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The current shift of therapy of chronic lymphocytic leukemia (CLL) towards novel targeted agents 
mandates the identification of molecular predictors to inform on who can still benefit from 
chemoimmunotherapy and who can be instead early considered for novel targeted agents. Fludarabine, 
cyclophosphamide, and rituximab (FCR) is the most effective chemoimmunotherapy regimen for the 
management of CLL and represents the current standard of care for young and fit patients devoid of TP53 
disruption. A retrospective multicenter cohort of 287 untreated patients receiving first-line FCR was 
analyzed by targeted next generation sequencing of 24 recurrently mutated genes in CLL. By univariate 
analysis adjusted for multiple comparisons BIRC3 mutations identify a poor prognostic subgroup of patients 
failing FCR (median progression free survival: 2.2 years, p < 0.001) similar to cases harboring TP53 mutations 
(median progression free survival: 2.6 years, p < 0.0001). BIRC3 mutations maintained an independent 
association with an increased risk of progression with a hazard ratio of 2.8 (95% confidence interval 1.4-
5.6, p = 0.004) in multivariate analysis adjusted for TP53 mutation, 17p deletion and IGHV mutation status. 
The functional implications of BIRC3 mutations are largely unexplored and little is known about the 
prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first line FCR. By 
immunoblotting analysis, we showed that the non-canonical NF-κB pathway is active in BIRC3 mutated cell 
lines and in primary CLL samples, as documented by the stabilization of MAP3K14 and by the nuclear 
localization of p52. In addition, BIRC3 mutated primary CLL cells are less sensitive to fludarabine. If 
validated, BIRC3 mutations may be used as a new molecular predictor to select high-risk patients for novel 






Le terapie innovative per la leucemia linfatica cronica (CLL) includono nuovi agenti i quali richiedono 
l'identificazione di predittori molecolari per determinare i pazienti che possono ancora beneficiare della 
chemio-immunoterapia e coloro che, invece, necessitano di trattamento con nuovi farmaci. La terapia di 
prima linea per pazienti giovani, in buone condizioni cliniche e privi di aberrazioni del gene TP53, prevede 
l’utilizzo dello schema immunochemioterapico FCR, la combinazione dei farmaci Fludarabina, 
Ciclofosfamide e Rituximab. Il DNA genomico di 287 pazienti, trattati con terapia secondo lo schema FCR, è 
stato raccolto alla diagnosi e sottoposto al sequenziamento di 24 geni ricorrentemente mutati nella CLL, 
mediante tecnica di Next Generation Sequencing (NGS). In analisi univariata, le mutazioni di BIRC3 
identificano un sottogruppo di pazienti con prognosi sfavorevole (sopravvivenza mediana libera da 
progressione: 2,2 anni, p <0,001) simile ai casi che presentano mutazioni di TP53 (sopravvivenza mediana 
libera da progressione: 2,6 anni, p <0,0001). Le mutazioni di BIRC3 rimangono associate ad un maggior 
rischio di progressione (HR) in analisi multivariata corretta per mutazione di TP53, delezione 17p e stato 
mutazionale di IGHV: HR 2,8 (95% I.C. 1,4-5,6, p = 0,004). Le implicazioni funzionali delle mutazioni di BIRC3 
sono in gran parte inesplorate e poco si conosce circa il loro impatto prognostico in coorti di pazienti trattati 
omogeneamente con FCR. Mediante analisi di immunoblotting è stato dimostrato che la via non canonica 
di NF-κB è attiva sia nelle linee cellulari BIRC3 mutate che nelle cellule primarie, come documentato dalla 
stabilizzazione di MAP3K14 e dalla localizzazione nucleare di p52. Inoltre, le cellule primarie BIRC3 mutate 
sono meno sensibili al trattamento con Fludarabina. Se validate, le mutazioni di BIRC3 potrebbero essere 
utilizzate come nuovo predittore molecolare per selezionare pazienti ad alto rischio per nuovi approcci 





Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the western world 
with marked genetic and clinical variability.1 The clinical course of CLL ranges from a very indolent condition, 
with a nearly normal life expectancy, to rapidly progressive leading to early death.2 Fludarabine, 
cyclophosphamide, and rituximab (FCR) is the most effective chemoimmunotherapy regimen for the 
management of CLL, and represents the current standard for untreated patients who are young and in good 
physical condition3,4 except for patients with TP53 alterations.5 Though the majority of CLL patients 
receiving FCR as frontline therapy are destined to relapse, a subgroup of cases may experience a durable 
first remission. The current shift of therapy of CLL towards novel targeted agents mandates the recognition 
of molecular predictors to identify patients who can still benefit from chemoimmunotherapy and those 
who should instead be considered for novel targeted agents upfront. In the case of FCR, the 
immunoglobulin heavy chain genes (IGHV) mutational status and Fluorescence In Situ Hybridization (FISH) 
karyotype stratify: i) low-risk patients carrying mutated IGHV genes and devoid of both del11q and del17p 
who maximally benefit from such treatment; ii) intermediate-risk patients harboring unmutated IGHV 
genes and/or del11q in the absence of del17p who are a case mix of good and poor responders to FCR; iii) 
high-risk patients harboring del17p who are unsuitable for chemoimmunotherapy.3 Deletion of 17p and 
TP53 mutations capture most, routinely analyzed in clinical practice, but not all patients who are refractory 
to chemo-immunotherapy, which prompts the identification of additional biomarkers associated with early 
failure of FCR.3-5 B-cell neoplasia often pirates signaling pathways by molecular lesions to promote survival 
and proliferation. Though according to bioinformatics criteria BIRC3 (also known as cIAP2) is one of the 
candidate driver genes of CLL, the functional implications of BIRC3 mutations are partially unexplored.7-9 
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Nuclear factor-κB (NF-κB) signaling is a key component CLL development and evolution.10 Two NF-κB 
pathways exist namely, canonical and noncanonical.11 The former is triggered by the B-cell receptor (BCR) 
signaling via the Bruton’s tyrosine kinase (BTK), while the latter is activated by members of the tumor 
necrosis factor (TNF) cytokine family.12 Upon receptor binding, the TRAF3/MAP3K14-TRAF2/BIRC3 negative 
regulatory complex of non-canonical NF-κB signaling is disrupted, MAP3K14 (also known as NIK), the central 
activating kinase of the pathway, is released and activated to induce the phosphorylation and proteasomal 
processing of p100, thereby leading to the formation of p52-containing NF-κB dimers. The p52 protein 
dimerizes with RelB to translocate into the nucleus, where it regulates gene transcription. BIRC3 is a 
negative regulator of non-canonical NF-κB. Physiologically, BIRC3 catalyzes MAP3K14 protein ubiquitination 
in a manner that is dependent on the E3 ubiquitinine ligase activity of its C-terminal RING domain. MAP3K14 
ubiquitination results into its proteasomal degradation.13 Also, little is known about the prognostic impact 





2. AIM OF THE STUDY 
 
We aimed at refining the genetic-based stratification of FCR-treated CLL patients.  
The aims of this study are: 
• To identify molecular predictors in FCR treated patients; 














3. MATERIALS AND METHODS 
3.1. Patients 
The study was designed as a retrospective observational analysis from a multicenter cohort of 287 (275 
with complete clinical and molecular data) untreated CLL receiving first-line therapy with FCR in 17 different 
hematological centers. The following biological material was collected: i) 280 tumor genomic DNA (gDNA) 
and 7 tumor RNA isolated from peripheral blood (PB) before treatment start; and ii) paired germline gDNA 
from saliva from 14 cases. Normal gDNA from 22 healthy donors was also used to set the experimental 
background of the deep next generation sequencing (NGS) approach. Tumor and normal gDNA was 
extracted according to standard procedures.14 Tumor RNA was extracted according to the TRIzol Reagent 
protocol (Life Technologies). The clinical database was updated in April 2018. Patients provided informed 
consent in accordance with local Institutional Review Board requirements and the Declaration of Helsinki. 
The study was approved by the Ethical Committee of the Ospedale Maggiore della Carità di Novara 
associated with the Amedeo Avogadro University of Eastern Piedmont (study number CE 67/14). 
 
3.2. Cancer personalized profiling by deep sequencing (CAPP-seq) 
A targeted resequencing gene panel15 was designed to include: i) coding exons plus splice site of 24 
CLL genes known to be implicated in CLL pathogenesis and/or prognosis; ii) 3’UTR of NOTCH1; and iii) 
enhancer and promoter region of PAX5 (size of the target region: 66627bp) (Table S1).8,9 Tumor and 
germline gDNA were quantified using the Quant-iTTM PicoGreen dsDNA Assay kit (ThermoFisher Scientific) 
and 400 ng were sheared through sonication (Covaris M220 focused-ultrasonicator) before library 
construction to obtain 200-bp fragments. The size of the DNA fragments was checked using the Bioanalyzer 
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(Agilent Technologies). The NGS libraries for gDNA were constructed using the KAPA Library Preparation Kit 
(Kapa Biosystems) and NGS libraries for RNA were constructed using RNA Hyper Kit (Roche) following the 
manufacturer’s instructions. Hybrid selection was performed with the custom SeqCap EZ Choice Library 
(Roche NimbleGen). Multiplexed libraries (n = 10 per run) were sequenced using 300-bp paired-end runs 
on a MiSeq sequencer (Illumina) to obtain a coverage of at least 2000x in >90% of the target region 
(66627bp) in 80% of cases (Table S2). 
 
3.3. Bioinformatic pipeline for variant calling after CAPP-seq 
Initially, FASTQ sequencing reads were deduped. We deduped FASTQ sequencing reads from gDNA by 
utilizing the FastUniq v1.1 software, that collapses as duplicate reads only those fragments (read pairs) with 
100% sequence identity that also share genomic coordinates. The same approach was also used to dedupe 
germline gDNA and normal gDNA from 22 healthy donors, to avoid the introduction of biases in variant 
calling due to the application of different deduplication protocols. Then, the deduped FASTQ sequencing 
reads were locally aligned to the hg19 version of the human genome assembly using the BWA v.0.6.2 
software with the default setting, and sorted, indexed and assembled into a mpileup file using SAMtools 
v.1. The aligned read families were processed with mpileup using the parameters -A -d 10000000. For cases 
provided with paired germline gDNA, single nucleotide variations and indels were called in tumor gDNA vs 
germline gDNA, respectively, with the somatic function of VarScan2 using the parameters min-coverage 1 
--min-coverage-normal 1 --min-coverage-tumor 1 --min-var-freq 0--min-freq-for-hom 0.75 --somatic-p-
value 0.05 --min-avg-qual 20 --strand-filter 1 --validation 1. For cases lacking paired germline gDNA, single 
nucleotide variations and indels were called in tumor gDNA using the CNS function of VarScan2 using the 
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parameters --min-coverage 0 --min-readge 2 --min-avg-qual 20 --min-var-freq 0 --min-freq-for-hom 0.75 --
p-value 0.05 --strand-filter 1 --output-vcf 1 --variants 0. The variants called by VarScan 2 were annotated 
using the SeattleSeq Annotation 138 tool by using the default setting. Variants annotated as SNPs according 
to dbSNP 138 (with the exception of TP53 variants that were manually curated and scored as SNPs according 
to the IARC TP53 database), intronic variants mapping > 2 bp before the start or after the end of coding 
exons, and synonymous variants were then filtered out. The following strict post-processing filters were 
then applied to the remaining variants to further improve variant call confidence. To filter out variants 
below the base-pair resolution background frequencies in gDNA across the selector, for cases provided with 
paired germline gDNA, the Fisher's exact test was used to test whether the frequency of the variant called 
by VarScan 2 was significantly higher from that called in the corresponding paired germline gDNA, after 
adjusting for multiple comparisons by Bonferroni test [multiple comparisons corrected p threshold = 
0.00000018761163, corresponding to alpha of 0.05/(66627 x 4 alleles per position]. Accordingly, variants 
represented in > 10 reads of the paired germline and/or variants with a somatic p value from VarScan2 > 
0.00000018761163 were no further considered. To filter out systemic sequencing errors, a database 
containing all germline and normal gDNA background allele frequencies was assembled. Based on the 
assumption that all background allele fractions follow a normal distribution, for both cases provided with 
paired germline gDNA and cases lacking paired gDNA, a Z-test was employed to test whether a given variant 
in the tumor gDNA differed significantly in its frequency from typical germline or normal gDNA background 
at the same position in all the other germline and normal gDNA samples, after adjusting for multiple 
comparisons by Bonferroni test [multiple comparisons corrected p threshold = 0.00000018761163, 
corresponding to alpha of 0.05/(66627 x 4 alleles per position]. Variants that did not pass this filter were no 
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further considered. Variant allele frequencies for the resulting candidate mutations and the background 
error rate were visualized using IGV.  
 
3.4. Statistical analysis 
Progression free survival (PFS) was the primary endpoint and was measured from date of treatment 
start to date of progression according to IWCLL-NCI guidelines (event), death (event) or last follow-up 
(censoring). Overall survival (OS) was measured from date of initial presentation to date of death from any 
cause (event) or last follow-up (censoring). Survival analysis was performed by Kaplan-Meier method and 
compared between strata using the Log-rank test. A false discovery rate approach was used to account for 
multiple testing, and adjusted p-values were calculated using the Bonferroni correction. A maximally 
selected rank statistic was used to determine the optimal cut-off for variant allele frequency (VAF) based 
on the Log-rank statistics. A cut-off of 3% of VAF was set for TP53 mutations and of 10% for all the other 
genes. The adjusted association between exposure variables and PFS was estimated by Cox regression. 
Internal validation of the multivariate analysis was performed using a bootstrap approach to estimate 
means and confidence intervals of hazard ratios (HR), and percentage of selection for each variable in the 
model. The number of bootstrap samples used was 1000. Statistical significance was defined as p value < 
0.05. The analysis was performed with the Statistical Package for the Social Sciences (SPSS) software v.24.0 




3.5. Cell studies 
The human CLL cell line MEC1, the SMZL cell lines SSK41, VL51, and the MCL cell lines MAVER-1, Z-138 
and JEKO-1 were cultured under standard conditions in RPMI-1640 medium with L-glutamine 
supplemented with 10% fetal calf serum (FCS), Penicillin (100 U/ml) and Streptomycin (100 U/ml) (Sigma 
Aldrich). Human HEK-293T cells were maintained in Iscove’s Modified Dulbecco Medium (IMDM) 
supplemented with 10% fetal calf serum, 100 U/ml penicillin, 100 U/ml streptomycin and 2mM L-glutamine 
(Sigma Aldrich) under identical conditions.  
Three primary cells samples known to harbor heterozygous inactivating mutations of BIRC3 were 
included in the experiments. Two BIRC3 wild type cases were used as controls. 
 
3.6. Western blot analysis 
The entire non-canonical NF-κB pathway was assessed using the following specific primary antibodies: 
anti-BIRC3 (Cell Signaling, #3130), anti-TRAF2 (Cell Signaling, #4712), anti-TRAF3 (Cell Signaling, #4729), 
anti-MAP3K14 (Cell Signaling, #4994), anti-Phospho-NF-κB2 p100 (Cell Signaling, #4810), anti-NF-κB2 
p100/p52 (Cell Signaling, #4882). Anti--actin (Sigma Aldrich, #A2066) was used as loading control. The 
Qproteome Nuclear Protein Kit (Qiagen) was used according to the manufacturer’s instructions to isolate 
nuclear proteins from cells. Anti-β-tubulin (Sigma Aldrich, #T5201) and anti-BRG1 (G-7) (Santa Cruz 
Biotechnology, #17796) were used as controls for the purity of the cytoplasmic and nuclear fractions, 
respectively. Horseradish peroxidase-conjugated goat anti-mouse (LI-COR, #926-80010) or anti-rabbit (LI-
COR, #926-80011) antibodies were used to highlight binding by enhanced chemiluminescence with the 
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Clarity Western ECL Substrate (Biorad). Image acquisition and densitometric analyses were performed using 
the Molecular Imager Gel Doc XR System and the Quantity One software (Biorad). 
 
3.7. RNA extraction and gene expression profiling 
Total RNA was extracted from exponentially growing cell lines by TRIzol reagent (Life Technologies), 
and retro-transcribed using the Reverse Transcription Kit (Applied Biosystems). Quantitative real-time PCR 
(qRT-PCR) was conducted with the Step One Plus apparatus (Step One software 2.0; Applied Biosystems) 
using commercially available TaqMan Gene expression assays (TNFAIP3: Hs00234713_m1; NFKB2: 
Hs00174517_m1; NFKBIA: Hs00153283_m1; NFKBIE: Hs00234431_m1; PLEK: Hs00950975_m1; WNT10: 
Hs00228741_m1; IL2RG: Hs00953624_m1; RELB: Hs00232389_m1; MALT1: Hs01120052_m1) (BIRC3: 
Hs00985031_g1) (Life Technologies). Reactions were done in triplicate from the same cDNA (technical 
replicates). The comparative CT method (ΔΔCT) was used to calculate relative expression levels of the gene 
under analysis, using GAPDH (Hs03929097_g1) as internal references.  
 
3.8. Knockdown of MAP3K14 by RNA interference  
Lentiviruses expressing 3 short hairpin RNAs (shRNAs) targeting MAP3K14, as well as the scrambled 
shRNA, were produced and cloned into the BamHI/HindIII cloning sites of the pGFP-C-shLenti vectors 
(OriGene Technologies). Within the 5’-LTR and 3’-LTR regions, each pGFP-C-shLenti vector contains an 
shRNA expression cassette driven by an U6 promoter, a puromycin resistance marker driven by a SV40 
promoter and a GFP driven by a CMV promoter. The shRNA expression cassette consists of 29 bp target-
gene-specific sequence, a 7 bp loop, and another 29 bp reverse complementary sequence, followed by a 
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TTTTTT termination sequence. The HEK293T cell line was co-transfected with expression (3 different pGFP-
C-MAP3K14-shLenti or pGFP-C-non-effective-shLenti) vectors and adjuvant vectors (pMDL, REV and VSV-
G). Fluorescence microscope was utilized to check the expression of the GFP in the transfected HEK293T 
cell line. After virus titration, the VL51 cell line was infected with lentiviruses harboring the shRNAs against 
MAP3K14 and the scrambled through a spinoculation protocol. After four days, infected cells were 
monitored by flow cytometry for the expression of the GFP and were selected by puromycin (1.5 µg/mL). 
Cell viability was monitored by Tripan blue counting. 
 
3.9. Inhibitor studies 
Cells were put under starvation in RPMI 0.1% Fetal Bovine Serum (FBS) 24h before treatment. Then 
they were seeded at 8000 cells per well in a 96-well U-bottom plate and treated with 1 µM, 5 µM and 10 
µM of Ibrutinib (PCI-32765, Selleckchem) or vehicle (DMSO). Relative growth was determined by a Cell-
Titer Glo (CTG) Luminescent Cell Viability Assay (Promega) 72h and 96h after treatment, according to the 
manufacturer’s instructions and luminescence was quantified using a Victor X (PerkinElmer) multilabel 
reader. Treatments were done in triplicate (biological replicates). 
 
3.10. In vitro drug responses in primary CLL cells 
Leukemic cells were purified using Ficoll-Hypaque (Sigma Aldrich) from PB of CLL patients. Staining 
with CD19 and CD5 confirmed that in all samples leukemic cells were >90%. Patients were then divided into 
BIRC3 mutated (MUT) or wild-type (WT). TP53 mutated samples (and BIRC3 WT) were selected as positive 
control (i.e., cells intrinsically resistant to therapies). Cells were cultured in RPMI 10% FCS (200 µl, all 
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reagents from Sigma) at a density of 5x106/ml and both dose- and time-dependent responses were 
analyzed. Specifically, CLL cells were exposed to fludarabine) for 24-48 hours. Fludarabine was used at 1-5-
10-25 µM and venetoclax at 5-10-50-100-500-2000 nM. 
 
3.11. Apoptosis assay 
Drug-induced apoptosis was measured using the eBioscience™ Annexin V Apoptosis Detection Kit APC 
(ThermoFisher) following the manufacturer’s instruction. Data were acquired using a FACSCanto II 
cytofluorimeter (BD Biosciences) and processed with DIVA v6.1.3 and FlowJo Version 9.01 (TreeStar). 













4. RESULTS  
 
4.1 Patients harboring BIRC3 mutations are at risk of failing FCR 
Mutational profiling was performed in 287 patients who received first line FCR. The baseline features 
of the study cohort were consistent with progressive, previously untreated CLL (Table 1). The median 
follow-up was 6.8 years, with a median PFS and OS of 4.6 and 11.7 years, respectively (Table 1) consistent 
with clinical trial cohorts.16 As expected, SF3B1 and NOTCH1 were the most frequently mutated genes 
identified in 13.9% and in 13.6% of patients respectively, followed by TP53 in 9.4% and ATM in 6.9% of 
patients, reflecting the data reported in previous studies.8,9,17 Overall, 154/287 (53.6%) cases harbored at 
least one non-synonymous somatic mutation in one of the 24 CLL genes included in our panel (range: 1-5 
mutation per patient), which is consistent with the typical mutational spectrum of the coding genome of 
CLL requiring first line treatment. (Figure 1; Table S3).8,9,18 Outside of the coding genome, we identified one 
single mutation in the 3’ region of NOTCH1 (c.*378A>G) already reported.8  
By univariate analysis adjusted for multiple comparisons, among the genes analyzed in our panel, only 
TP53 mutations (median PFS of 2.6 years; p < 0.0001) and BIRC3 mutations (median PFS of 2.2 years; p < 
0.001) (Figure 2 A) associated with significantly shorter PFS (Table 2). The PFS after FCR of BIRC3 mutated 
patients was similar to that of cases harboring TP53 disruption (Figure 2 B). Consistently, BIRC3 mutated 
patients had a lower likelihood of achieving complete response (22.2%) at the end of FCR compared to 
BIRC3 wild type cases (76.7%; p=0.001). Well known molecular prognostic biomarkers of CLL, such as 
unmutated IGHV gene status and 17p deletion also associated with a significantly shorter PFS, supporting 
the representativeness of the study cohort (Table 2). By multivariate analysis including variables showing a 
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multiplicity adjusted significant association with PFS, BIRC3 mutations maintained an independent 
association with PFS, with a HR of 2.8 (95% C.I. 1.4-5.6, p = 0.004) (Table 2). 
 
4.2 BIRC3 mutations associate with activation of non-canonical NF-κB signaling 
In order to comprehensively map unique BIRC3 mutations in CLL, we compiled somatically confirmed 
variants identified in the current CLL study cohort with those identified in previous studies17 or listed in 
public CLL mutation catalogues (Figure 3 A). Virtually all BIRC3 mutations were represented by frameshift 
or stop codons clustering in two hotspot regions comprised between amino acid 367-438 and amino acid 
537-564. BIRC3 variants were predicted to generate aberrant truncated transcripts causing the elimination 
or truncation of the C-terminal RING domain of the BIRC3 protein. The RING domain of BIRC3 harbors the 
E3 ubiquitin ligase activity that is essential for proteasomal degradation of MAP3K14, the central activating 
kinase of the noncanonical NF-κB signaling. This observation points to non-canonical NF-κB activation 
through MAP3K14 stabilization as the predicted functional consequence of BIRC3 mutations in CLL. The 
non-canonical NF-κB signaling was profiled by immunoblotting in B-cell tumor cell lines and primary CLL 
cells with different genetic make-up in the non-canonical NF-κB pathway to verify whether BIRC3 mutations 
lead to constitutive non-canonical NF-κB activation. Additional genetic features of the above mentioned 
cell lines and primary CLL cells are shown in Table S4. In the VL51 SMZL cell line and in the MEC1 CLL cell 
lines, both harboring endogenous truncating mutations of the BIRC3 gene, non-canonical NF-κB signaling 
was constitutively active, as documented by the stabilization of MAP3K14, phosphorylation of NF-κB2, its 
processing from p100 to p52, as well as nuclear localization of p52 (Figure 3 B-D). Consistent with the 
biochemical clues of non-canonical NF-κB activation, the gene expression signature of the VL51 and MEC1 
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cell lines was significantly enriched of non-canonical NF-κB target genes (Figure 3 E-F). Non-canonical NF-
κB signaling in BIRC3 mutated cells was consistent with that of MCL cell lines known to harbor a disrupted 
TRAF3/MAP3K14-TRAF2/BIRC3 negative regulatory complex by loss of TRAF3 or TRAF2.19 As BIRC3 mutated 
cell lines, also primary CLL samples harboring inactivating mutations of BIRC3 showed stabilization of 
MAP3K14 and NF-κB2 processing from p100 to p52 (Figure 3 C), thus confirming that non-canonical NF-κB 
activation is also a feature of primary cells harboring BIRC3 variants. 
MAP3K14 was genetically targeted by shRNA to test whether BIRC3 mutated cells are addicted of its 
stabilization. Compared to non-targeting shRNA, the most efficient anti MAP3K14 shRNA-D resulted in a 
partial silencing of MAP3K14 and in a decreased NF-κB2 processing from p100 to p52. This translated into a 
reduced cell viability of the BIRC3 mutated VL51 cell line transduced with shRNA-D. This observation 
indicates that MAP3K14 stabilization is a vulnerability of BIRC3 mutated cells (Figure 4).  
In order to test the contribution of BTK to noncanonical NF-κB signaling when it is activated through 
BIRC3 mutations, BIRC3 mutated cell lines, as well as cell lines harboring a disrupted or competent 
TRAF3/MAP3K14-TRAF2/BIRC3 negative regulatory complex were treated with ibrutinib at different dosage 
and non-canonical NF-κB signaling activation probed by immunoblotting of the NF-κB2 processing from 
p100 to p52. Processing from p100 to p52 was unaffected by ibrutinib treatment in cell lines harboring 
BIRC3 mutations (Figure 5) or a disrupted TRAF3/MAP3K14-TRAF2/BIRC3 negative regulatory complex 
consistent with the notion that BIRC3 mutations activate non-canonical NF-κB by bypassing BTK blockade 




4.3 BIRC3 mutations confer resistance to fludarabine in primary CLL cells  
We performed in vitro pharmacological studies on primary CLL cells to verify the vulnerabilities of 
BIRC3 mutated cells. CLL cells purified from patients carrying BIRC3 mutations were treated with increasing 
doses of fludarabine. Drug-induced apoptosis was compared to samples harboring TP53 mutations, which 
represent a control for fludarabine resistance. CLL cells devoid of genetic lesions on either BIRC3 or TP53 
were adopted as a control cohort for fludarabine sensitivity. Molecular characteristic of the ex-vivo CLL cells 
are listed in Table S5. BIRC3 mutated cells showed a delayed fludarabine-induced cell death, as no response 
was observed after 24-hour treatment, at variance with TP53 and BIRC3 wild type samples. At this time 
point, cell viability curves of BIRC3 mutated samples were almost completely overlapping with that of TP53 
disrupted samples, which are known to be fludarabine resistant (Figure 6 A). At 48 hours, BIRC3 mutated 
cells had viability that was lower than that of TP53 mutated samples, but higher than that of TP53 and BIRC3 
wild type samples (Figure 6 B). 
In order to assess whether BIRC3 mutations interfere with apoptosis, primary CLL cells were treated 
with venetoclax. Venetoclax treatment resulted in similar reduction of cell viability in BIRC3 mutated cells, 
TP53 mutated cells and BIRC3/TP53 wild type cells (Figure 6 C, D). Such divergent sensitivity to fludarabine 
and venetoclax of BIRC3 mutated CLL cells indirectly suggests that BIRC3 mutations likely affect the 
upstream DNA damage response pathway rather than the downstream apoptosis among mechanisms of 








The results of this study provide the evidence that: i) BIRC3 mutated patients fail FCR 
chemoimmunotherapy analogous to cases harboring TP53 disruption; and that ii) BIRC3 mutations 
associate with activation of the non-canonical NF-κB pathway and with resistance to fludarabine in vitro. 
The mere presence of somatic mutations is insufficient to implicate a gene in cancer. Cancer geneticists 
and bioinformaticians differentiate “passengers” events, likely being randomly acquired, to distinguish 
them from mutations targeting candidate “cancer driver” genes, likely implicated in the tumor biology, 
according to a statistical definition. Any given gene is labeled as candidate “cancer driver” if it harbors 
somatic point mutations at a statistically significant rate or pattern in cancer samples. In CLL, more than 40 
genes fulfill the statistical definition of candidate “cancer driver”, including BIRC3, but few of them are 
biologically validated (i.e. SF3B1, NOTCH1, TP53, ATM, FBXW7).8,9,20-23 The BIRC3 (Baculoviral IAP Repeat 
Containing 3) gene codes for a protein that ubiquitinates and negatively regulates the central activating 
kinase of the non-canonical NF-κB pathway, namely MAP3K14.24,25 In lymphoid malignancies, the NF-κB 
pathway is a pivotal and positive mediator of cell proliferation and survival.7,26,27 In CLL, BIRC3 mutations 
are absent in monoclonal B-cell lymphocytosis (MBL) patients, are rare at the time of diagnosis (3-4%), but 
are detectable in approximately 25% of fludarabine refractory patients.17 In this study, we verified the 
biological consequences of BIRC3 mutations by showing that they associate with activation of the non-
canonical NF-κB pathway, that BIRC3 mutated lymphoid cells are addicted of non-canonical NF-κB pathway, 
and that BIRC3 mutated CLL are resistant to fludarabine both in vitro and in patients. It still remains to be 
clarified whether NF-κB activation is the only molecular pathway that causes chemo-refractoriness in BIRC3 
mutated CLL or whether other mechanisms are also involved.27-31  
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The introduction of FCR has represented a breakthrough in the management of young and fit CLL 
patients with an improvement in both PFS and OS compared to previous regiments. In both clinical trials 
and real life cohorts,3-5 IGHV mutation status and TP53 disruption sorted out as strong predictors of poor 
response to FCR. However, these molecular biomarkers do not fully capture all high-risk patients destined 
to relapse. We propose BIRC3 mutations as a new biomarker for the identification of high-risk patients 
failing FCR similarly to cases harboring TP53 disruption. If validated in independent series, BIRC3 mutations 
may turn out as a new molecular predictor of FCR resistance to be use for selecting patients to be treated 
with novel targeted agents.  
Non-canonical NF-κB activation by BIRC3 mutations by-pass the block of BTK by ibrutinib. Consistently, 
NF-κB activation and cell survival is unaffected by ibrutinib in both CLL cells (our study) and mantle cell 
lymphoma cells.19 If this pre-clinical evidence will be validated in ibrutinib-treated patients, BIRC3 mutations 
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Table 1. Clinical data of FCR-treated CLL patients    
   
Characteristics Number of patients (%) Total 
Male 198 (69.0%) 
N=287 
Female 89 (31.0%) 
Binet A 33 (11.5%) 
N=287 
Binet B-C 254 (88.5%) 
IGHV mutated 100 (35.7%) 
N=280 
IGHV unmutated 180 (64.3%) 
17p deletion 13 (4.7%) 
N=274 
No 17p deletion 261 (95.3%) 
11q deletion 47 (17.2%) 
N=273 
No 11q deletion 226 (82.8%) 
13q deletion 111 (40.7%) 
N=273 
No 13q deletion 162 (50.3%) 
Trisomy 12 50 (18.4%) 
N=272 
No Trisomy 12 222 (81.6%) 
      
Median Follow-up (years) 6.8   
Median PFS  4.6  
PFS % (7-years) 31.0%   
Median OS (years) 11.7  
OS % (7-years) 75.5%   
   











Table 2. Univariate and multivariate analysis of PFS                      
                
 Univariate analysis     Multivariate analysis   Internal bootstrapping validation 






95% CI P  P*   HR LCI UCI P   HR LCI UCI 
Bootstrapping 
selection (%) 
Binet A 40.3% 4.5 2.4-6.6 
0.356 -  
- - - 
-  
- - - 
- 
Binet B-C 30.0% 4.6 3.8-5.4  - - -  - - - 
IGHV mutated 49.3% 6.5 3.8-9.2 
<0.001 0.003 
  - - - 
0.001 
  - - - 
98.8% 
IGHV unmutated 23.0% 3.9 3.5-4.4   1.8 1.3 2.6   1.9 1.3 2.7 
No 11q deletion 33.4% 5.0 4.2-5.9 
0.025 0.700  
- - - 
-  
- - - 
- 
11q deletion 13.9% 3.6 2.4-4.9  - - -  - - - 
No 17p deletion 33.0% 4.8 4.1-5.6 
<0.0001 <0.0001 
  - - - 
<0.0001 
  - - - 
99.5% 
17p deletion nr 1.1 0-2.6   4.0 2.2 7.5   4.9 2.5 9.8 
TP53 Wild type 33.8% 5.4 4.3-5.8 
<0.0001 <0.001  
- - - 
0.030  
- - - 
73.3% 
TP53 Mutated nr 2.8 2.0-3.5  1.7 1.1 2.8  1.8 1.1 3 
BIRC3 Wild type 32.2% 4.8 4.1-5.6 
<0.001 0.005 
  - - - 
0.004 
  - - - 
91.1% 
BIRC3 Mutated nr 2.2 0.9-3.5   2.8 1.4 5.6   3.4 1.6 7.3 
EGR2Wild type 31.5% 4.7 3.9-5.4 
0.015 0.420  
- - - 
-  
- - - 
- 
EGR2Mutated nr 1.5 0-3.8  - - -  - - - 
ATM Wild type 32.5% 4.8 4.1-5.6 
0.029 0.812 
  - - - 
- 
  - - - 
- 
ATM Mutated nr 3.2 2.4-4.1   - - -   - - - 
P, P-value; P*, Bonferroni correction; PFS, progression free survival; CI, confidence interval; HR, hazard ratio; LCI, lower confidence interval; UCI, upper confidence interval; 
IGHV, immunoglobulin heavy variable gene; nr, not reached 
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8. FIGURES LEGENDS 
 
Figure 1. Mutational profile of the FCR-treated cohort. Case-level mutational profiles of 287 patients FCR-
treated patients. Each column represents one tumor sample, each row represents one gene. The fraction 
of tumors with mutations in each gene is plotted on the right. The number and type of mutations in each 
patient is plotted above the heat map. Mutations are highlighted in red. IGHV mutational status, 17p 
deletion and 11q deletion are plotted in the bottom of the heatmap. 
 
Figure 2. Kaplan-Meier estimates of progression free survival in BIRC3 mutated patients. (A) Cases 
harboring BIRC3 mutations are represented by the red line. Cases wild type for this gene are represented 
by the blue line. (B) Cases harboring BIRC3 mutations are represented by the red line. Cases harboring 
TP53 disruption (including TP53 mutation and/or 17p deletion) are represented by the yellow line. 
Patients devoid of BIRC3 mutation and TP53 disruption are represented by the blue line. The Log-rank 
statistics p values are indicated adjacent curves. 
 
Figure 3: Non-canonical NF-κB pathway is active in BIRC3 mutated CLL cell lines and primary samples. 
(A) Disposition of BIRC3 mutations across the protein. The mutations identified by Landau et al.9, Puente 
et al.8 and from public CLL mutation catalogue (COSMIC v85) are plotted in grey. Individual BIRC3 
mutations identified in the current studied cohort and in our previous study17 are plotted in red. (B) 
Western blot analysis of BIRC3 protein expression and NF-κB2 activation and processing in the SMZL cell 
lines SSK41, VL51 and in the CLL cell line MEC1, carrying wild-type or disrupted BIRC3. The MAVER-1 and 
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Z-138 cell lines were used as positive controls of non-canonical NF-κB activation, harboring genetic 
activation of non-canonical NF-kB signaling. The JEKO-1 and HEK 293T cell lines were used as negative 
controls for non-canonical NF-κB signalling. α-actin was used as a loading control. Color codes indicate 
the gene status in each cell lines. The aberrant BIRC3 band expressed in MEC1 and VL51 cell lines 
correspond in size to the predicted BIRC3-truncated protein, encoded by the mutant allele. (C) Western 
blot analysis showing BIRC3 expression and NF-kB2 processing in purified primary tumor cells from 5 CLL 
and SMZL patients carrying wild-type or disrupted BIRC3. Color codes indicate the gene status in each cell 
lines. The aberrant BIRC3 bands in patients 09321, 14462 and 12603 correspond in size to the predicted 
BIRC3-truncated protein encoded by the mutant allele. α-actin was used as a loading control. (D) Western 
blot of whole cell extract, cytoplasmic or nuclear fractions of the SMZL and CLL cell lines probed for the 
NF-κB2 subunits p100 and p52. The MAVER-1 and Z-138 cell lines served as positive controls while the 
JEKO-1 and HEK 293T cell lines were used as negative controls. ß-tubulin and BRG1 served as controls for 
the purity of the cytoplasmic and nuclear fractionations, respectively. (E) GSEA enrichment score and 
distribution of non-canonical NF-κB target genes along the rank of transcripts differentially expressed in 
the SMZL cell lines SSK41, VL51 and in the CLL cell line MEC1. The JEKO-1 cell line was used as negative 
control. (F) Validation of non-canonical NF-κB target genes expression in the same SMZL and CLL cell lines 
as determined by quantitative real-time RT-PCR. Changes of genes expression were normalized to GAPDH 
expression; relative quantities were log2 normalized to control samples (MCL cell line JEKO-1). 
 
Figure 4: Knockdown of MAP3K14 by RNA interference in VL51 cells. (A) Western blot analysis for 
MAP3K14 expression and for NF-κB2 processing of p100 to p52. (B) VL51 cells viability assessed by trypan 
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blue after transduction with lentiviral vectors expressing the shRNAD_MAP3K14 (in red), a scrambled 
shRNA (in blu), and in non transfected cells (in green). 
 
Figure 5: Non-canonical NF-κB pathway is not switched off by ibrutinib in BIRC3 mutated cell lines. 
Western blot showing p100/p52 expression in (A) MEC1 and (B) VL51 cell lines that harbors BIRC3 
mutations. (C) MAVER-1 and (D) Z-138 cell lines, known to be affected by noncanonical NF-κB pathway 
gene mutations and resistant to ibrutinib were used as positive controls. (E) JEKO-1 cell line, known to be 
devoid of NF-κB pathway gene mutations and sensitive to ibrutinib was used as negative control. All cell 
lines were treated with different concentrations of ibrutinib for 72 and 96 hours. 
 
Figure 6: Responses of primary cells lines to fludarabine and venetoclax. Viability of BIRC3 mutated (n = 
6 patients, red line), TP53 mutated (n = 8 patients, black line) and wild type (n = 7 patients, blue line) 
primary CLL cells treated with different concentrations of fludarabine for (A) 24 hours and (B) 48 hours 
and of venetoclax for (C) 24 hours and (D) 48 hours The pairwise p values have been listed in the tables 














Figure 2. Kaplan-Meier estimates of progression free survival in BIRC3 mutated patients. 
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9. SUPPLEMENTARY TABLES 
 
Table S1. Target region   




hg19 coding exon start 
plus splice site (2bp) 
hg19 coding exon stop 
plus splice site (2bp) 
NRAS chr1 115251156 115251277 
 chr1 115252188 115252351 
 chr1 115256419 115256601 
 chr1 115258669 115258781     
XPO1 chr2 61705955 61706103 
 chr2 61708318 61708418 
 chr2 61709513 61709676 
 chr2 61710090 61710228 
 chr2 61711070 61711242 
 chr2 61712901 61713099 
 chr2 61715298 61715408 
 chr2 61715721 61715908 
 chr2 61717775 61717913 
 chr2 61719168 61719335 
 chr2 61719458 61719618 
 chr2 61719700 61719885 
 chr2 61720048 61720190 
 chr2 61721027 61721228 
 chr2 61722588 61722750 
 chr2 61724012 61724144 
 chr2 61725806 61725929 
 chr2 61725998 61726050 
 chr2 61726846 61727031 
 chr2 61729129 61729177 
 chr2 61729382 61729447 
 chr2 61749744 61749820 
 chr2 61753553 61753658 
 chr2 61760905 61761032     
SF3B1 chr2 198257027 198257187 
 chr2 198257694 198257914 
 chr2 198260778 198261054 
 chr2 198262707 198262842 
 chr2 198263183 198263307 
 chr2 198264777 198264892 
 chr2 198264974 198265160 
 chr2 198265437 198265662 
 chr2 198266122 198266251 
 chr2 198266464 198266614 
 chr2 198266707 198266856 
 chr2 198267278 198267552 
 chr2 198267671 198267761 
 chr2 198268307 198268490 
 chr2 198269798 198269903 
 chr2 198269997 198270198 
 chr2 198272720 198272845 
 chr2 198273091 198273307 
 chr2 198274492 198274733 
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 chr2 198281463 198281637 
 chr2 198283231 198283314 
 chr2 198285150 198285268 
 chr2 198285751 198285859 
 chr2 198288530 198288700 
 chr2 198299694 198299723     
MYD88 chr3 38180153 38180521 
 chr3 38181353 38181491 
 chr3 38181877 38182061 
 chr3 38182246 38182341 
 chr3 38182621 38182777     
FBXW7 chr4 153244035 153244303 
 chr4 153245334 153245548 
 chr4 153247156 153247385 
 chr4 153249358 153249543 
 chr4 153250822 153250939 
 chr4 153251882 153252022 
 chr4 153253746 153253873 
 chr4 153258952 153259090 
 chr4 153268080 153268225 
 chr4 153271192 153271278 
 chr4 153332453 153332955     
IRF4 chr6 393150 393370 
 chr6 394818 395009 
 chr6 395844 395937 
 chr6 397105 397254 
 chr6 398825 398937 
 chr6 401421 401779 
 chr6 405015 405132 
 chr6 407452 407600     
NFKBIE chr6 44226953 44227023 
 chr6 44227777 44228021 
 chr6 44228185 44228278 
 chr6 44229360 44229587 
 chr6 44230294 44230401 
 chr6 44232716 44233502     
POT1 chr7 124464016 124464130 
 chr7 124465304 124465413 
 chr7 124467266 124467361 
 chr7 124469306 124469398 
 chr7 124475331 124475470 
 chr7 124481025 124481234 
 chr7 124482859 124483019 
 chr7 124486994 124487054 
 chr7 124491924 124492007 
 chr7 124493024 124493194 
 chr7 124499009 124499168 
 chr7 124503402 124503696 
 chr7 124510963 124511097 
 chr7 124532318 124532436 
 chr7 124537217 124537227     
BRAF chr7 140434397 140434572 
 chr7 140439610 140439748 
 chr7 140449085 140449220 
 chr7 140453073 140453195 
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 chr7 140453985 140454035 
 chr7 140476710 140476890 
 chr7 140477789 140477877 
 chr7 140481374 140481495 
 chr7 140482819 140482959 
 chr7 140487346 140487386 
 chr7 140494106 140494269 
 chr7 140500160 140500283 
 chr7 140501210 140501362 
 chr7 140507758 140507864 
 chr7 140508690 140508797 
 chr7 140534407 140534674 
 chr7 140549909 140550014 
 chr7 140624364 140624503     
NOTCH1 chr9 139390512 139392020     
NOTCH1_3'UTR chr9 139388893 139390524     
PAX5 chr9 37370906 37371645 
 chr9 37033543 37034202     
EGR2 chr10 64572967 64574230 
 chr10 64575619 64575789     
NFKB2 chr10 104155676 104155777 
 chr10 104155999 104156101 
 chr10 104156155 104156296 
 chr10 104156471 104156590 
 chr10 104156650 104156822 
 chr10 104157048 104157175 
 chr10 104157273 104157452 
 chr10 104157727 104157852 
 chr10 104157958 104158064 
 chr10 104158131 104158290 
 chr10 104158485 104158631 
 chr10 104159034 104159264 
 chr10 104159323 104159485 
 chr10 104159826 104159961 
 chr10 104160024 104160258 
 chr10 104160401 104160591 
 chr10 104160693 104160816 
 chr10 104160926 104161098 
 chr10 104161225 104161325 
 chr10 104161491 104161684 
 chr10 104161794 104161926 
 chr10 104161998 104162143     
ATM chr11 108098352 108098425 
 chr11 108098501 108098617 
 chr11 108099903 108100052 
 chr11 108106395 108106563 
 chr11 108114678 108114847 
 chr11 108115513 108115755 
 chr11 108117689 108117856 
 chr11 108119658 108119831 
 chr11 108121426 108121801 
 chr11 108122562 108122760 
 chr11 108123542 108123641 
 chr11 108124539 108124768 
 chr11 108126940 108127069 
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 chr11 108128206 108128335 
 chr11 108129711 108129804 
 chr11 108137896 108138071 
 chr11 108139135 108139338 
 chr11 108141789 108141875 
 chr11 108141976 108142135 
 chr11 108143257 108143336 
 chr11 108143447 108143581 
 chr11 108150216 108150337 
 chr11 108151720 108151897 
 chr11 108153435 108153608 
 chr11 108154952 108155202 
 chr11 108158325 108158444 
 chr11 108159702 108159832 
 chr11 108160327 108160530 
 chr11 108163344 108163522 
 chr11 108164038 108164206 
 chr11 108165652 108165788 
 chr11 108168012 108168111 
 chr11 108170439 108170614 
 chr11 108172373 108172518 
 chr11 108173578 108173758 
 chr11 108175400 108175581 
 chr11 108178622 108178713 
 chr11 108180885 108181044 
 chr11 108183136 108183227 
 chr11 108186548 108186640 
 chr11 108186736 108186842 
 chr11 108188098 108188250 
 chr11 108190679 108190787 
 chr11 108192026 108192149 
 chr11 108196035 108196273 
 chr11 108196783 108196954 
 chr11 108198370 108198487 
 chr11 108199746 108199967 
 chr11 108200939 108201150 
 chr11 108202169 108202286 
 chr11 108202604 108202766 
 chr11 108203487 108203629 
 chr11 108204611 108204697 
 chr11 108205694 108205838 
 chr11 108206570 108206690 
 chr11 108213947 108214100 
 chr11 108216468 108216637 
 chr11 108218004 108218094 
 chr11 108224491 108224609 
 chr11 108225536 108225603 
 chr11 108235807 108235947 
 chr11 108236050 108236235     
BIRC3 chr11 102195241 102196095 
 chr11 102196195 102196298 
 chr11 102198781 102198863 
 chr11 102199626 102199678 
 chr11 102201728 102201974 
 chr11 102206695 102206953 
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 chr11 102207489 102207534 
 chr11 102207638 102207833     
KRAS chr12 25368375 25368496 
 chr12 25378546 25378709 
 chr12 25380166 25380348 
 chr12 25398206 25398318     
MAP2K1 chr15 66679683 66679767 
 chr15 66727362 66727577 
 chr15 66729081 66729232 
 chr15 66735615 66735697 
 chr15 66736991 66737047 
 chr15 66774090 66774219 
 chr15 66777325 66777531 
 chr15 66779563 66779632 
 chr15 66781550 66781616 
 chr15 66782053 66782103 
 chr15 66782837 66782955     
MGA chr15 41961082 41962166 
 chr15 41988262 41989231 
 chr15 41991040 41991149 
 chr15 41991251 41991367 
 chr15 41999915 42000067 
 chr15 42000291 42000416 
 chr15 42002878 42003557 
 chr15 42005338 42005704 
 chr15 42019367 42019614 
 chr15 42021351 42021557 
 chr15 42026699 42026802 
 chr15 42028368 42028906 
 chr15 42032240 42032411 
 chr15 42034733 42035380 
 chr15 42040824 42041135 
 chr15 42041298 42042823 
 chr15 42046624 42046775 
 chr15 42049955 42050057 
 chr15 42052510 42052737 
 chr15 42053926 42054058 
 chr15 42054316 42054570 
 chr15 42057073 42057270 
 chr15 42058191 42059488     
TP53 chr17 7572927 7573010 
 chr17 7573925 7574035 
 chr17 7576851 7576928 
 chr17 7577017 7577157 
 chr17 7577497 7577610 
 chr17 7578175 7578291 
 chr17 7578369 7578556 
 chr17 7579310 7579592 
 chr17 7579698 7579723 
 chr17 7579837 7579912     
IKZF3 chr17 37922032 37922756 
 chr17 37933893 37934030 
 chr17 37944500 37944637 
 chr17 37947658 37947846 
 chr17 37948915 37949196 
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 chr17 37985629 37985751 
 chr17 37988320 37988434 
 chr17 38020322 38020429     
RPS15  chr19 1438374 1438477 
 chr19 1438785 1438911 
 chr19 1440007 1440262 
 chr19 1440337 1440471     
SAMHD1 chr20 35521335 35521471 
 chr20 35526223 35526364 
 chr20 35526841 35526949 
 chr20 35532558 35532654 
 chr20 35533765 35533908 
 chr20 35539619 35539738 
 chr20 35540862 35540957 
 chr20 35545123 35545235 
 chr20 35545350 35545454 
 chr20 35547765 35547924 
 chr20 35555583 35555657 
 chr20 35559161 35559280 
 chr20 35563430 35563594 
 chr20 35569440 35569516 
 chr20 35575139 35575209 
 chr20 35579837 35580046     
ASXL1 chr20 30946548 30946665 
 chr20 30954176 30954279 
 chr20 30955479 30955582 
 chr20 30956807 30956936 
 chr20 31015920 31016061 
 chr20 31016117 31016235 
 chr20 31017130 31017244 
 chr20 31017693 31017866 
 chr20 31019113 31019297 
 chr20 31019375 31019492 
 chr20 31020672 31020798 
 chr20 31021076 31021730 
 chr20 31022224 31025151     
ZMYM3 chrX 70460766 70460960 
 chrX 70461075 70461196 
 chrX 70462018 70462276 
 chrX 70462818 70462936 
 chrX 70463677 70463832 
 chrX 70464150 70464322 
 chrX 70464638 70464745 
 chrX 70465187 70465337 
 chrX 70465516 70465694 
 chrX 70465834 70465950 
 chrX 70466201 70466364 
 chrX 70466443 70466544 
 chrX 70467193 70467362 
 chrX 70467582 70467758 
 chrX 70468010 70468164 
 chrX 70468286 70468376 
 chrX 70468534 70468653 
 chrX 70468867 70469021 
 chrX 70469309 70469531 
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 chrX 70469874 70470055 
 chrX 70470280 70470578 
 chrX 70471026 70471096 
 chrX 70471406 70471453 




Table S2. Target region with ≥1000X and ≥2000X coverage 
 
Material Sample ID 
Target Region Coverage (%) 
≥ 1000X ≥ 2000X 
RNA 3389 29.6 19.9 
RNA 3390 49.8 28 
RNA 3392 86.8 31.1 
RNA 3393 55.2 33.6 
RNA 3394 58.6 37.5 
RNA 3395 91.7 38.8 
RNA 3396 62 39.5 
gDNA 4822 66.5 44.5 
gDNA 4937 88.2 46.7 
gDNA 4997 92.3 88.2 
gDNA 5564 67.6 49 
gDNA 5868 86 58 
gDNA 6415 92.6 64 
gDNA 7274 91 67.4 
gDNA 7302 86.5 73.8 
gDNA 8461 98.3 74.5 
gDNA 9248 98.4 74.5 
gDNA 9289 95.9 75.1 
gDNA 9291 89.7 75.2 
gDNA 10676 100 99.9 
gDNA 10851 89.2 75.4 
gDNA 12162 98.3 76.3 
gDNA 12640 98.9 90.2 
gDNA 12955 99.8 97.4 
gDNA 13318 99.9 99.2 
gDNA 13426 66.4 46.5 
gDNA 13443 72.2 40.7 
gDNA 14261 90.2 78 
gDNA 14293 95.8 78.9 
gDNA 14419 94.2 79.3 
gDNA 14462 99.9 96.3 
gDNA 14687 100 99.8 
gDNA 14821 69.6 40.3 
gDNA 14830 75.4 31.6 
gDNA 15065 99.7 79.5 
gDNA 15257 97.8 79.6 
gDNA 15280 98.3 80 
gDNA 15361 95.7 80.7 
gDNA 15367 95.6 80.9 
gDNA 15426 87.8 80.9 
gDNA 15448 68.7 39.2 
gDNA 15467 96.2 82.5 
gDNA 15505 96.3 82.8 
gDNA 15522 96.7 83.6 
gDNA 15537 97.8 83.7 
gDNA 15562 96.5 83.7 
gDNA 15597 93.8 84.6 
gDNA 15871 98.5 84.8 
gDNA 15891 97.5 85 
gDNA 15997 91.3 85.6 
47 
 
gDNA 16243 99.9 98.8 
gDNA 17548 99.6 97.4 
gDNA 17698 86.6 68 
gDNA 18723 97.7 86 
gDNA 18736 98.1 86.2 
gDNA 19184 97.5 86.5 
gDNA 19189 97 87 
gDNA 19363 86.9 74.3 
gDNA 19402 99.7 97.9 
gDNA 19405 100 99.6 
gDNA 19533 98.2 87 
gDNA 20010 98.6 87.3 
gDNA 20196 90.1 87.6 
gDNA 20802 98.1 87.8 
gDNA 20803 98.2 88 
gDNA 20804 99.1 91.2 
gDNA 20805 98.6 90.3 
gDNA 20806 98.2 89.1 
gDNA 20807 98.4 90.1 
gDNA 20808 96.2 89.4 
gDNA 20809 96.3 89.7 
gDNA 20810 99.8 91.1 
gDNA 20811 98.4 90.5 
gDNA 20812 95.0 90.1 
gDNA 20813 98.6 90.4 
gDNA 20814 98.4 90.4 
gDNA 20815 99.1 90.7 
gDNA 20816 99.2 90.9 
gDNA 20817 95.6 91.2 
gDNA 20818 99.4 91.7 
gDNA 20819 98.4 91.7 
gDNA 20820 98.8 92.3 
gDNA 20821 98.8 92.3 
gDNA 20822 98.2 92.5 
gDNA 20823 99.3 92.8 
gDNA 20824 98.9 92.9 
gDNA 20825 99.3 93.1 
gDNA 20826 98.7 93.3 
gDNA 20827 98.1 93.4 
gDNA 20828 99.8 93.4 
gDNA 20829 99 93.5 
gDNA 20830 98.2 93.7 
gDNA 20831 98.9 93.7 
gDNA 20832 99.2 93.8 
gDNA 20833 99 93.9 
gDNA 20834 99.5 94.5 
gDNA 20835 99.3 94.6 
gDNA 20844 99.3 94.7 
gDNA 20845 98.4 94.9 
gDNA 20846 99.4 95.3 
gDNA 20847 99.9 95.4 
gDNA 20848 99.1 95.4 
gDNA 20849 99.4 95.4 
gDNA 20850 98.8 95.4 
gDNA 20851 99.2 95.6 
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gDNA 20852 99.2 95.6 
gDNA 20853 99.7 95.9 
gDNA 20854 99.7 95.9 
gDNA 20855 99 96.1 
gDNA 20856 99.2 96.1 
gDNA 20857 99.4 96.2 
gDNA 20858 99.4 96.3 
gDNA 20859 99.9 96.5 
gDNA 20860 99.8 96.5 
gDNA 20861 99.4 96.6 
gDNA 20864 99.4 96.6 
gDNA 20865 99.1 96.7 
gDNA 20866 99.7 96.7 
gDNA 20867 99.3 96.8 
gDNA 20868 99.4 96.8 
gDNA 20869 99.8 96.8 
gDNA 20870 99.6 96.8 
gDNA 20871 99.1 96.9 
gDNA 20872 99.3 96.9 
gDNA 20873 99.1 96.9 
gDNA 20874 99.9 97 
gDNA 20875 99.4 97.1 
gDNA 20876 99.2 97.1 
gDNA 20896 99.4 97.1 
gDNA 20897 99.1 97.2 
gDNA 21006 99.4 97.2 
gDNA 21007 99.6 97.2 
gDNA 21008 99.3 97.2 
gDNA 21009 99.4 97.3 
gDNA 21010 99.4 97.3 
gDNA 21011 99.1 97.3 
gDNA 21012 99.2 97.3 
gDNA 21013 99.5 97.3 
gDNA 21014 99.4 97.4 
gDNA 21015 99.6 97.4 
gDNA 21016 99.3 97.4 
gDNA 21017 99.2 97.4 
gDNA 21018 99.3 97.4 
gDNA 21019 99.3 97.5 
gDNA 21020 99.5 97.5 
gDNA 21021 99.4 97.5 
gDNA 21022 99.2 97.5 
gDNA 21045 99.2 97.6 
gDNA 21046 99.6 97.6 
gDNA 21047 99.4 97.6 
gDNA 21048 99.5 97.6 
gDNA 21049 99.4 97.7 
gDNA 21050 99.3 97.7 
gDNA 21051 99.5 97.7 
gDNA 21052 99.6 97.7 
gDNA 21053 99.6 97.7 
gDNA 21054 99.5 97.8 
gDNA 21095 99.9 97.8 
gDNA 21096 99.6 97.8 
gDNA 21097 99.4 97.8 
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gDNA 21098 99.6 97.8 
gDNA 21099 99.4 97.8 
gDNA 21189 99.5 97.8 
gDNA 21190 99.5 97.8 
gDNA 21191 99.4 98 
gDNA 21193 99.8 98 
gDNA 21194 99.7 98 
gDNA 21195 99.7 98 
gDNA 21196 99.5 98 
gDNA 21197 99.4 98.1 
gDNA 21198 99.6 98.1 
gDNA 21199 99.5 98.1 
gDNA 21291 99.7 98.1 
gDNA 21292 99.5 98.1 
gDNA 21293 99.6 98.1 
gDNA 21294 99.8 98.2 
gDNA 21295 99.7 98.2 
gDNA 21296 99.6 98.2 
gDNA 21297 99.8 98.2 
gDNA 21299 99.8 98.2 
gDNA 21300 99.5 98.3 
gDNA 21301 99.6 98.3 
gDNA 21302 99.8 98.3 
gDNA 21303 99.5 98.3 
gDNA 21304 99.5 98.3 
gDNA 21305 99.9 98.3 
gDNA 21306 99.6 98.4 
gDNA 21307 99.7 98.4 
gDNA 21308 99.6 98.4 
gDNA 21309 99.8 98.4 
gDNA 23050 99.7 98.4 
gDNA 23051 99.6 98.5 
gDNA 23052 99.7 98.5 
gDNA 23053 99.9 98.5 
gDNA 23054 99.6 98.5 
gDNA 23055 99.8 98.5 
gDNA 23056 99.9 98.5 
gDNA 23057 99.6 98.5 
gDNA 23058 99.8 98.5 
gDNA 23059 99.8 98.5 
gDNA 23060 99.9 98.6 
gDNA 23061 99.8 98.6 
gDNA 23062 99.7 98.6 
gDNA 23063 99.6 98.6 
gDNA 23064 99.7 98.6 
gDNA 23065 99.7 98.7 
gDNA 23066 99.7 98.7 
gDNA 23067 99.6 98.7 
gDNA 23068 99.9 98.7 
gDNA 23069 99.8 98.7 
gDNA 23070 99.9 98.7 
gDNA 23071 99.6 98.7 
gDNA 23072 100 98.7 
gDNA 23073 99.9 98.7 
gDNA 23074 99.7 98.7 
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gDNA 23075 99.9 98.7 
gDNA 23076 99.9 98.8 
gDNA 23077 99.7 98.8 
gDNA 23078 99.7 98.8 
gDNA 23079 99.6 98.8 
gDNA 23080 99.9 98.8 
gDNA 23081 99.9 98.8 
gDNA 23082 99.8 98.8 
gDNA 23083 99.9 98.8 
gDNA 23084 99.9 98.8 
gDNA 23085 99.9 98.9 
gDNA 23086 99.9 98.9 
gDNA 23087 99.9 98.9 
gDNA 23088 99.9 98.9 
gDNA 23089 99.9 98.9 
gDNA 23090 99.9 98.9 
gDNA 23091 99.7 98.9 
gDNA 23092 99.5 98.9 
gDNA 23093 99.8 98.9 
gDNA 23094 99.7 98.9 
gDNA 23095 99.9 98.9 
gDNA 23096 99.9 98.9 
gDNA 23097 99.9 98.9 
gDNA 23098 99.9 98.9 
gDNA 23099 99 99 
gDNA 23100 99.9 99 
gDNA 23101 99.7 99 
gDNA 23102 99.9 99 
gDNA 23103 99.9 99 
gDNA 23104 99.9 99 
gDNA 23105 99.9 99 
gDNA 23106 99.7 99.1 
gDNA 23107 99.9 99.1 
gDNA 23108 99.9 99.1 
gDNA 23109 99.9 99.1 
gDNA 23110 99.9 99.1 
gDNA 23111 99.9 99.1 
gDNA 23112 99.9 99.1 
gDNA 23113 99.9 99.1 
gDNA 23114 99.9 99.1 
gDNA 23115 99.8 99.1 
gDNA 23116 99.9 99.1 
gDNA 23117 99.9 99.1 
gDNA 23118 99.9 99.2 
gDNA 23119 99.9 99.2 
gDNA 23120 99 99.2 
gDNA 23121 99.9 99.2 
gDNA 23122 99.8 99.2 
gDNA 23123 99.9 99.2 
gDNA 23124 99.9 99.3 
gDNA 23125 99.9 99.3 
gDNA 23126 99.9 99.3 
gDNA 23127 99.9 99.4 
gDNA 23128 99.9 99.4 
gDNA 23129 99.9 99.4 
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gDNA 23130 99.9 99.4 
gDNA 23131 99.9 99.4 
gDNA 23132 99.9 99.4 
gDNA 23133 99.9 99.4 
gDNA 23134 99.9 99.5 
gDNA 23135 99.9 99.5 
gDNA 23136 99.8 99.5 
gDNA 23137 99.9 99.5 
gDNA 23138 100 99.5 
gDNA 23139 99.9 99.5 
gDNA 23140 100 99.6 
gDNA 23141 100 99.6 
gDNA 23142 99.9 99.6 
gDNA 23143 99.9 99.6 
gDNA 23144 100 99.8 
gDNA 23145 100 99.9 




Table S3. Somatic non-synonymous mutations discovered in tumor samples 
  
ID Sample Gene RefSeq #CHROM POS REF VAR cDNA AA VAF in tumor samples  
3392 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 34.4 (386/1119) 
3396 TP53 NM_000546.5 chr17 7577610 T TC c.673-2A>G - 5.13 (44/857) 
4822 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 36 (581/1614) 
4937 SF3B1 NM_012433.2 chr2 198267371 G T c.1986C>A p.H662Q 31.15 (3202/10278) 
4997 TP53 NM_000546.5 chr17 7578394 T A c.536A>T p.H179L 89.57 (2233/2491) 
5564 ATM NM_000051.3 chr11 108206593 G A c.8173G>A p.D2725N 18.78 (496/2641) 
5564 ATM NM_000051.3 chr11 108224528 C T c.8707C>T p.P2903S 23.06 (751/3257) 
5564 POT1 NM_015450.2 chr7 124493080 C A c.422G>T p.G272V 15.23 (545/3579) 
7302 NOTCH1 NM_017617.3 chr9 139390759 CG C c.7431_7431delC p.A2478fs*5 43.4 (447/1030) 
10676 BRAF NM_004333.4 chr7 140534588 A T c.325T>A p.F109I 40.4 (5204/12861) 
10676 SF3B1 NM_012433.2 chr2 198266834 T C  c.2098A>G p.K700E 20.3 (2415/11876) 
12162 MGA NM_001164273.1 chr15 41989130 A AT c.1922_1923insT p.T642fs*15 11.59 (361/3115) 
12162 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 41.64 (513/1232) 
12955 FBXW7 NM_033632 chr4 153258983 G A c.832C>T p.R278* 15.86 (550/3467) 
13443 BIRC3 NM_001165.4 chr11 102207656 AC A c.1639_1639delC p.Q547fs*21 10.5 (55/523) 
14293 TP53 NM_000546.5 chr17 7578553 T C c.377A>G p.Y126C 13.65 (731/5353) 
14419 ATM NM_000051.3 chr11 108170513 AT A c.5079_5079delT p.D1693fs*21 86.18 (2014/2332) 
14419 MGA NM_001164273.1 chr15 42054328 TAA T c.7513_7514delAA p.K2504fs*31 36.5 (803/2199) 
14419 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 21 (285/1355) 
14419 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 12.79 (169/1320) 
14462 BIRC3 NM_001165.4 chr11 102201928 TA T c.1281_1281delA p.R428fs*19 31.17 (944/3028) 
14462 BIRC3 NM_001165.4 chr11 102207519 AG A c.1609_1609delG p.E537fs*31 27 (678/2511) 
14462 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 36.9 (1803/4877) 
14687 ATM NM_000051.3 chr11 108201101 C T c.7468C>T p.L2490F  33.8 (5139/15183) 
15257 SF3B1 NM_012433.2 chr2 198266611 C T c.2225G>A p.G742D 30.16 (2557/8475) 
15257 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 30.4 (2882/9475) 
15280 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 18.28 (647/3535) 
15361 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 38.84 (3004/7720) 
15367 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 10.13 (220/2171) 
15367 TP53 NM_000546.5 chr17 7577539 G A c.742C>T p.R248W 38.49 (1411/3662) 
15448 POT1 NM_015450.2 chr7 124537225 C CA c.2_3insT  initiating Methionine lost 27.2 (61/224) 
15448 TP53 NM_000546.5 chr17 7578190 T G c.659A>C p.Y220S 23.5 (2002/8499) 
15505 KRAS NM_033360.2 chr12 25398255 G T c.64C>A p.Q22K 21.95 (1222/5559) 
15505 SAMHD1 NM_015474 chr20 35526905 CA C c.1545_1545delT p.I515fs*35 43.16 (3089/5442) 
53 
 
15505 SAMHD1 NM_015474 chr20 35526278 C T c.1693G>A p.A565T 50.02 (3232/6457) 
15505 TP53 NM_000546.5 chr17 7577548 C T c.733G>A p.G245S 19.95 (979/4903) 
15537 BIRC3 NM_001165.4 chr11 102201966 G GA c.1318_1319insA p.S441fs*3 10.34 (156/1505) 
15537 BIRC3 NM_001165.4 chr11 102201960 G T c.1312G>T p.E438* 11.79 (186/1586) 
15537 BIRC3 NM_001165.4 chr11 102207656 AC A c.1639_1639delC p.Q547fs*21 20.99 (390/1853) 
15597 SF3B1 NM_012433.2 chr2 198267484 G A c.1873C>T p.R625C 10.8 (677/6265) 
15597 TP53 NM_000546.5 chr17 7577610 T C c.673-2A>G - 22.44 (724/3227) 
15891 TP53 NM_000546.5 chr17 7579372 GC G c.314_314delG p.G105fs*18 18.41 (648/3505) 
15891 TP53 NM_000546.5 chr17 7577610 T A c.673-2A>G - 33.55 (787/2208) 
16243 ATM NM_000051.3 chr11 108160350 C T c.4258C>T p.L1420F 31.7 (2184/6880) 
16243 SF3B1 NM_012433.2 chr2 198267489 T C c.1868A>G p.Y623C 16.9 (1066/6299) 
17698 NOTCH1 NM_017617.3 chr9 139390800 AG A c.7390_7390delC p.L2464fs*13 44.2 (1955/4422) 
18723 TP53 NM_000546.5 chr17 7578208 T C c.641A>G p.H214R 7.01 (502/7158) 
18736 FBXW7 NM_033632.3 chr4 153253770 C T c.963G>A p.W321* 23.23 (1103/4742) 
18736 IRF4 NM_002460.3 chr6 394951 T G c.347T>G p.L116R 14.58 (1202/8245) 
19184 ZMYM3 NM_201599 chrX 70472961 CA C c.144_144delT p.G49fs*64 18.86 (458/2423) 
19363 SF3B1 NM_012433.2 chr2 198267359 C G c.1998G>C p.K666N 26.67 (1767/6625) 
19363 XPO1 NM_003400.3 chr2 61719186 T C c.1871A>G p.D624G 28.31 (1129/3987) 
19405 NOTCH1 NM_017617.3 chr9 139390585 C T c.7606G>A p.V2536I 32.98 (6297/19088) 
19533 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 44.82 (3115/6948) 
20010 SF3B1 NM_012433.2 chr2 198266822 T A c.2110A>T p.I704F 12.14 (753/6200) 
20010 SF3B1 NM_012433.2 chr2 198267371 G T c.1986C>A p.H662Q 15.4 (686/4454) 
20010 TP53 NM_000546.5 chr17 7578413 C G c.517G>C p.V173L 11.54 (261/2260) 
20196 IKZF3 NM_012481.4 chr17 37985732 G A c.71C>T p.A24V 51.19 (2296/4484) 
20802 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 37.13 (822/2209) 
20803 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 23.3 (916/3923) 
20804 IKZF3 NM_012481.4 chr17 37947776 A C c.485T>G p.L162R 27.22 (1316/4834) 
20804 ZMYM3 NM_201599 chrX 70472962 AG A c.143_143delC p.P48fs*65 24.43 (579/2369) 
20807 MYD88 NM_002468.4 chr3 38182641 T C c.794T>C p.L265P 21.99 (1087/4940) 
20808 SF3B1 NM_012433.2 chr2 198267360 T G c.1997A>C p.K666T 22.11 (1782/8056) 
20810 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 34.54 (1636/4731) 
20811 SF3B1 NM_012433.2 chr2 198266713 C T c.2219G>A p.G740E 10.96 (424/3865) 
20812 IKZF3 NM_012481.4 chr17 37947776 A C c.485T>G p.L162R 42.39 (3787/8922) 
20812 NOTCH1 NM_017617.3 chr9 139390975 G A c.7216C>T p.Q2406* 41.51 (2956/7119) 
20812 RPS15 NM_001018.3 chr19 1440439 C T c.413C>T p.S138F 14.08 (309/2187) 
20813 MGA NM_001164273.1 chr15 42028793 TA T c.4332_4332delA p.L1444fs*36 32.37 (1714/5295) 
20818 ASXL1 NM_015338.5 chr20 31024704 G A c.4189G>A p.G1397S 48.02 (2053/4270) 
20820 XPO1 NM_003400.3 chr2 61719472 C A c.1711G>T p.E571* 10.68 (240/2247) 
20821 BRAF NM_004333.4 chr7 140481402 C G c.1406G>C p.G469A 35.17 (1666/4732) 
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20821 EGR2 NM_000399.3 chr10 64573167 C G c.1231G>C p.D411H 34.43 (2156/6253) 
20822 ATM NM_000051.3 chr11 108126954 GA G c.2138_2138delA p.T713fs*20 10.87 (332/3055) 
20822 BIRC3 NM_001165.4 chr11 102201945 GAA G c.1298_1299delAA p.R434fs*3 10.88 (420/3857) 
20822 IRF4 NM_002460.3 chr6 394951 T G c.347T>G p.L116R 29.37 (1664/5661) 
20823 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 25.53 (1971/5742) 
20827 IKZF3 NM_012481.4 chr17 37947776 A C c.485T>G p.L162R 41.37 (1814/4377) 
20831 ATM NM_000051.3 chr11 108178641 CG C c.5693_5693delG p.R1898fs*19 11.94 (151/1265) 
20832 ATM NM_000051.3 chr11 108175463 A T c.5558A>T p.D1853V 50.28 (2634/5237) 
20832 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 44.23 (2407/5441) 
20833 BIRC3 NM_001165.4 chr11 102207704 CA C c.1687_1687delA p.E564fs*4 17.15 (996/5794) 
20833 ZMYM3 NM_201599 chrX 70472444 A T c.662T>A p.L221* 85.83 (1950/2268) 
20834 KRAS NM_033360.2 chr12 25398262 C G c.57G>C p.L19F 28.85 (1123/3893) 
20844 TP53 NM_000546.5 chr17 7579419 AG A c.267_267delC p.S90fs*33 3.16 (86/2723) 
20845 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 10.23 (424/4132) 
20845 RPS15 NM_001018.3 chr19 1440436 C T c.413C>T p.S138F 22.71 (422/1857) 
20845 XPO1 NM_003400.3 chr2 61719186 T C c.1871A>G p.D624G 38.73 (2087/5385) 
20846 TP53 NM_000546.5 chr17 7578176 C T c.672+1G>A - 28.1 (726/2584) 
20847 BRAF NM_004333.4 chr7 140453136 A T c.1799T>A p.V600E 17.69 (820/4633) 
20849 SF3B1 NM_012433.2 chr2 198267359 C A c.1998G>T p.K666N 20.2 (1033/5110) 
20850 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 12.16 (460/3779) 
20852 ATM NM_000051.3 chr11 108143456 C G c.3161C>G p.P1054R 48.39 (4558/9414) 
20852 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 81.93 (3260/3973) 
20852 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 13.94 (718/5150) 
20853 ATM NM_000051.3 chr11 108143456 C G c.3161C>G p.P1054R 51.51 (2525/4894) 
20853 BIRC3 NM_001165.4 chr11 102207684 AC A c.1667_1667delC p.T556fs*12 49.27 (2360/4789) 
20853 SF3B1 NM_012433.2 chr2 198266611 C T c.2225G>A p.G742D 43.96 (1797/4083) 
20855 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 13.6 (507/3712) 
20857 EGR2 NM_000399.3 chr10 64573248 G T c.1150C>A p.H384N 27.07 (1313/4848) 
20857 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 41.62 (1463/3505) 
20860 MGA NM_001164273.1 chr15 42028430 AT A c.3969_3969delT p.Y1323* 22.38 (1126/5032) 
20860 TP53 NM_000546.5 chr17 7577123 A C c.815T>G p.V272G 5.11 (248/4847) 
20861 EGR2 NM_000399.3 chr10 64573248 G T c.1150C>A p.H384N 10.1 (720/7121) 
20861 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 23.64 (1042/4396) 
20868 SF3B1 NM_012433.2 chr2 198267360 T G c.1997A>C p.K666T 19.46 (1184/6077) 
20868 SF3B1 NM_012433.2 chr2 198267361 T C c.1996A>G p.K666E 20.3 (1249/6152) 
20870 ATM NM_000051.3 chr11 108160480 T G c.4388T>G p.F1463C 49.82 (3142/6305) 
20872 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 14.06 (532/3781) 
20872 TP53 NM_000546.5 chr17 7577108 C A c.830G>T p.C277F 5.21 (344/6605) 
20875 XPO1 NM_003400.3 chr2 61719471 T C c.1712A>G p.E571G 20.02 (1086/5420) 
55 
 
20876 SF3B1 NM_012433.2 chr2 198267361 T C c.1996A>G p.K666E 41.44 (2390/5766) 
20897 BIRC3 NM_001165.4 chr11 102207656 AC A c.1639_1639delC p.Q547fs*21 75.16 (838/1115) 
21007 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 30.48 (1704/5585) 
21007 TP53 NM_000546.5 chr17 7578460 A T c.470T>A p.V157D 6.84 (511/7466) 
21008 SF3B1 NM_012433.2 chr2 198266709 C A c.2223G>T p.K741N 10.72 (452/4217) 
21010 IRF4 NM_002460.3 chr6 394951 T G c.347T>G p.L116R 54.95 (2315/4210) 
21010 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 33.41 (449/1340) 
21011 BRAF NM_004333.4 chr7 140481402 C G c.1406G>C p.G469A 41.92 (1971/4693) 
21012 FBXW7 NM_033632.3 chr4 153247289 G A c.1513C>T p.R505C 42.2 (1834/4342) 
21012 NOTCH1 NM_017617.3 chr9 139391200 C CCACA c.6990_6991insTGTG p.A2331fs*24 30.69 (421/1353) 
21012 TP53 NM_000546.5 chr17 7578535 T A  c.395A>T p.K132M 7.85 (244/3109) 
21013 SF3B1 NM_012433.2 chr2 198266611 C T c.2225G>A p.G742D 13.18 (653/4951) 
21014 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 20.25 (873/4302) 
21015 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 46.48 (1517/3261) 
21015 SF3B1 NM_012433.2 chr2 198266821 A T  c.2111T>A p.I704N 47.02 (2466/5244) 
21015 TP53 NM_000546.5 chr17 7577117 A T c.821T>A p.V274D 16.17 (876/5410) 
21015 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 13.72 (811/5912) 
21016 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 14.06 (532/3781) 
21017 ATM NM_000051.3 chr11 108143456 C G c.3161C>G p.P1054R 78.34 (3292/4200) 
21017 IKZF3 NM_012481.4 chr17 37985732 G A c.71C>T p.A24V 47.79 (3051/6380) 
21018 TP53 NM_000546.5 chr17 7578400 G A c.530C>T p.P177L 5.38 (288/5353) 
21018 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 22.72 (2210/9718) 
21019 FBXW7 NM_033632.3 chr4 153245446 G A c.1745C>T p.S582L 17.19 (1314/7640) 
21019 TP53 NM_000546.5 chr17 7577548 C A c.733G>T p.G245C 3.19 (199/6226) 
21019 TP53 NM_000546.5 chr17 7577538 C T c.743G>A p.R248Q 4.28 (273/6383) 
21019 TP53 NM_000546.5 chr17 7577106 G A c.832C>T p.P278S 5.56 (440/7903) 
21019 TP53 NM_000546.5 chr17 7577120 C T c.818G>A p.R273H 15.34 (1286/8382) 
21021 TP53 NM_000546.5 chr17 7577121 G A c.817C>T p.R273C 26.49 (656/2473) 
21022 NOTCH1 NM_017617.3 chr9 139390861 G A c.7330C>T p.Q2444* 18.12 (1219/6726) 
21045 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 11.07 (350/3163) 
21046 XPO1 NM_003400.3 chr2 61719471 T A c.1712A>T p.E571V 14.34 (663/4625) 
21047 MGA NM_001164273.1 chr15 42042450 TC T c.6646_6646delC p.Q2216fs*22 29.7 (1549/5215) 
21047 SF3B1 NM_012433.2 chr2 198267361 T C c.1996A>G p.K666E 40.33 (1914/4745) 
21048 MAP2K1 NM_002755 chr15 66727453 A G c.169A>G p.K57E 13.53 (710/5245) 
21048 RPS15 NM_001018.3 chr19 1440423 G A c.400G>A p.G134R 20.62 (632/3064) 
21050 ATM NM_000051.3 chr11 108143456 C G c.3161C>G p.P1054R 46.61 (2718/5829) 
21050 NOTCH1 NM_017617.3 chr9 139390765 CG C c.7425_7425delC p.V2475* 19.53 (739/3781) 
21050 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 20.79 (794/3815) 
21051 SF3B1 NM_012433.2 chr2 198267491 C A c.1866G>T p.E622D 14.5 (744/5129) 
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21095 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 10.71 (596/5558) 
21095 TP53 NM_000546.5 chr17 7578375 GCTAT G c.551_554delATAG p.D184fs*62 36.15 (2539/7008) 
21098 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 77.44 (3453/4448) 
21099 TP53 NM_000546.5 chr17 7578461 C A c.469G>T p.V157F 17.9 (1408/7866) 
21189 RPS15 NM_001018.3 chr19 1440414 C T c.391C>T p.P131S 30.92 (983/3178) 
21190 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 17.07 (320/1873) 
21190 ZMYM3 NM_201599 chrX 70461153 TA T c.3807_3807delT p.I1270fs*2 12.8 (210/1563) 
21191 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 22.05 (484/2190) 
21193 RPS15 NM_001018.3 chr19 1440436 C T c.413C>T p.S138F 21.18 (270/1275) 
21193 TP53 NM_000546.5 chr17 7577570 C G c.711G>C p.M237I 23.01 (421/1829) 
21194 TP53 NM_000546.5 chr17 7578460 A T c.470T>A p.V157D 33.24 (995/2990) 
21196 EGR2 NM_000399.3 chr10 64573332 C T c.1066G>A p.E356K 46.87 (2378/5070) 
21196 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 29.99 (702/2340) 
21296 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 23.85 (899/3770) 
21300 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 13.51 (302/2235) 
21300 ZMYM3 NM_201599 chrX 70471427 CT C c.691_691delA p.S231fs*26 55.71 (1093/1962) 
21301 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 28.54 (764/2673) 
21301 SAMHD1 NM_015474 chr20 35526278 C T c.1693G>A p.A565T 52.67 (2193/4164) 
21302 ATM NM_000051.3 chr11 108200961 G A c.7328G>A p.R2443Q 13.56 (480/3539) 
21304 IKZF3 NM_012481.4 chr17 37947776 A C c.485T>G p.L162R 14.63 (936/6389) 
21304 MGA NM_001164273.1 chr15 42021500 CA C c.3797_3797delA p.Q1266fs*25 24.72 (1448/5854) 
21304 MGA NM_001164273.1 chr15 41988277 A AT c.1069_1070insT p.A358fs*5 26.82 (1201/4466) 
21307 RPS15 NM_001018.3 chr19 1440421 T G c.398T>G p.I133S 39.94 (1203/3010) 
21308 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 13.08 (289/2206) 
23050 BIRC3 NM_001165.4 chr11 102207656 AC A c.1639_1639delC p.Q547fs*21 28.5 (2711/9510) 
23050 TP53 NM_000546.5 chr17 7578542 G C c.388C>G p.L130V 41.1 (1803/4386) 
23054 ATM NM_000051.3 chr11 108155201 G A c.3993+1G>A - 30 (1106/3695) 
23054 ATM NM_000051.3 chr11 108143456 C G c.3161C>G p.P1054R 52.2 (2399/4595) 
23054 RPS15 NM_001018.3 chr19 1440432 C T  c.409C>T p.H137Y  35.4 (955/2699) 
23057 ATM NM_000051.3 chr11 108142006 C T c.2950C>T p.Q984* 94.5 (1768/1870) 
23057 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 53.4 (1504/2814) 
23057 ZMYM3 NM_201599 chrX 70469355 G A c.1426C>T p.Q476* 82.8 (3236/3906) 
23058 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 16.57 (643/3879) 
23058 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 40.75 (2095/5133) 
23063 ATM NM_000051.3 chr11 108160350 C T c.4258C>T p.L1420F 47.8 (3023/6316) 
23063 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 12.2 (786/6441) 
23065 MYD88 NM_002468.4 chr3 38182641 T C c.794T>C p.L265P 17.3 (184/1063) 
23068 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 49.6 (3380/6806) 
23070 BIRC3 NM_001165.4 chr11 102207672 C T c.1654C>T p.Q552* 17.82 (784/4399) 
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23070 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 27.71 (908/3276) 
23074 SF3B1 NM_012433.2 chr2 198266611 C T c.2225G>A p.G742D 46.2 (3284/7103) 
23075 ATM NM_000051.3 chr11 108114679 G A c.497-1G>A - 39.35 (1672/4249) 
23075 ATM NM_000051.3 chr11 108172375 T A c.5178T>A p.C1726* 39.99 (2785/6963) 
23075 ATM NM_000051.3 chr11 108160350 C T c.4258C>T p.L1420F 49.89 (3499/7013) 
23075 RPS15 NM_001018.3 chr19 1440432 C T c.409C>T p.H137Y 16.41 (462/2814) 
23076 XPO1 NM_003400.3 chr2 61719303 C A c.1754G>T p.C585F 48.6 (3396/6977) 
23077 ATM NM_000051.3 chr11 108119720 G GA c.1126_1127insA p.S377fs*2 27.7 (1263/4552) 
23077 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 49 (3488/7113) 
23078 EGR2 NM_000399.3 chr10 64573248 G T c.1150C>A p.H384N 48.7 (3886/7965) 
23079 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 10.8 (530/4866) 
23079 NRAS NM_002524.4 chr1 115258744 C T c.38G>A p.G13D 49.2 (1884/3822) 
23080 SF3B1 NM_012433.2 chr2 198266494 T C c.2342A>G p.D781G 18.87 (783/4148) 
23082 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 29.36 (1477/5030) 
23082 SAMHD1 NM_015474 chr20 35555633 CAT C c.646_647delAT p.M216fs*2 39.39 (1530/3884) 
23082 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 35.09 (2582/7357) 
23085 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 26.24 (415/1581) 
23086 FBXW7 NM_033632.3 chr4 153247366 C T c.1436G>A p.R479Q 44.08 (1792/4067) 
23086 MGA NM_001164273.1 chr15 42042600 AG A c.6796_6796delG p.N2267fs*68 72.5 (1002/1382) 
23088 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 18.17 (714/3929) 
23089 NOTCH1 NM_017617.3 chr9 139390145 T C c.*378A>G - 10 (507/5041) 
23089 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 29.7 (1230/4141) 
23091 TP53 NM_000546.5 chr17 7577538 C T c.743G>A p.R248Q 44.2 (2624/5938) 
23093 MYD88 NM_002468.4 chr3 38182641 T C c.794T>C p.L265P 50.22 (4631/9220) 
23094 ASXL1 NM_015338.5 chr20 31023328 CT C c.2814_2814delT p.A939fs*6 10.3 (750/7309) 
23094 ASXL1 NM_015338.5 chr20 31022628 G T c.2113G>T p.E705* 32.6 (2222/6818) 
23094 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 11.6 (794/6847) 
23096 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 15.47 (442/2857) 
23097 KRAS NM_033360.2 chr12 25378562 C T c.436G>A p.A146T 14.8 (970/6527) 
23106 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 17.4 (611/3508) 
23106 POT1 NM_015450.2 chr7 124499045 T C c.668A>G p.Y223C 38.3 (1714/4469) 
23106 RPS15 NM_001018.3 chr19 1440417 G A c.394G>A p.G132S 39.1 (1066/2723) 
23107 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 14.2 (746/5269) 
23108 SF3B1 NM_012433.2 chr2 198265476 T C c.2681A>G p.D894G 23.7 (1147/4840) 
23112 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 38.5 (2460/6375) 
23113 TP53 NM_000546.5 chr17 7577551 C T c.730G>A p.G244S 55.6 (1837/3302) 
23115 EGR2 NM_000399.3 chr10 64573332 C T c.1066G>A p.E356K 16.35 (1084/6629) 
23118 NOTCH1 NM_017617.3 chr9 139390793 CGTGGGCA C c.7391_7397delTGCCCAC p.L2464fs*11 29.7 (603/2028) 
23118 POT1 NM_015450.2 chr7 124537227 T A c.1A>T p.M1L 23.9 (579/2414) 
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23118 ZMYM3 NM_201599 chrX 70469448 C A c.1333G>T p.G445* 15 (332/2200) 
23118 ZMYM3 NM_201599 chrX 70469002 G T c.1488C>A p.Y496* 49.6 (1038/2089) 
23120 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 25.22 (915/3627) 
23121 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 20.3 (645/3175) 
23124 IKZF3 NM_183229.2 chr17 37947776 A C c.485T>G p.L162R 14.2 (764/5348) 
23127 ATM NM_000051.3 chr11 108143456 C G c.3161C>G p.P1054R 49.66 (5187/10444) 
23128 NFKBIE NM_004556.2 chr6 44232738 TGTAA T c.759_762delTTAC p.Y254fs*13 19.5 (786/4029) 
23129 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 15.34 (393/2561) 
23129 SF3B1 NM_012433.2 chr2 198266711 T C c.2221A>G p.K741E 45.5 (3228/7081) 
23129 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 45.4 (4136/9097) 
23131 SF3B1 NM_012433.2 chr2 198267491 C A c.1866G>T p.E622D 39 (3585/9180) 
23132 MGA NM_001164273.1 chr15 41961741 C T c.649C>T p.Q217* 29.8 (2153/7211) 
23132 XPO1 NM_003400.3 chr2 61719472 C T c.1711G>A p.E571K 38 (2909/7641) 
23133 IKZF3 NM_183229.2 chr17 37947776 A C c.485T>G p.L162R 21.04 (1759/8358) 
23133 NOTCH1 NM_017617.3 chr9 139390648 CAG C c.7541_7542delCT p.P2514fs*4 11.85 (574/4841) 
23133 ZMYM3 NM_201599 chrX 70469358 G A c.1423C>T p.Q475* 21.18 (805/3800) 
23135 MYD88 NM_002468.4 chr3 38182259 T C c.695T>C p.M232T 29.1 (1890/6486) 
23137 SF3B1 NM_012433.2 chr2 198266611 C T c.2225G>A p.G742D 31.9 (2402/7525) 
23140 SF3B1 NM_012433.2 chr2 198267369 G A c.1988C>T p.T663I 39.18 (2933/7485) 
23141 IKZF3 NM_183229.2 chr17 37947776 A C c.485T>G p.L162R 44.6 (2695/6031) 
23143 SF3B1 NM_012433.2 chr2 198266834 T C c.2098A>G p.K700E 23.88 (1942/8129) 
23145 ATM NM_000051.3 chr11 108155085 A G c.3878A>G p.N1293S 36.6 (2670/7285) 
23145 IKZF3 NM_183229.2 chr17 37947776 A C c.485T>G p.L162R 38.14 (2282/5983) 
 
 Table S4. 11q deletion, 17p deletion and TP53 mutational status of tumor cell 
lines and primary CLL cells 
    
Sample ID 11q deleted 17p deleted TP53 mutated  
MEC1 no yes no 
SSK41 no no no 
VL51 no yes no 
JEKO1 no yes yes 
MAVER1 yes yes yes 
Z138 no no no 
9321 no no no 
14462 yes no no 
12603 no no no 
11731 no no no 






Table S5. Primary cell lines divided into BIRC3/TP53 mutated or wild-type (WT).  
 
Sample ID IGHV TP53 BIRC3 
13443 Unmutated WT Mutated 
9696 Unmutated WT Mutated 
9482 Unmutated WT Mutated 
14324 Unmutated WT Mutated 
PMN019 Unmutated WT Mutated 
PMN012 Unmutated WT Mutated 
11480 Unmutated Mutated WT 
13344 Unmutated Mutated WT 
7916 Unmutated Mutated WT 
13730 Unmutated Mutated WT 
9311 Unmutated Mutated WT 
PMN081 Mutated Mutated WT 
14326 Unmutated Mutated WT 
11214 Unmutated Mutated WT 
10666 Unmutated WT WT 
11815 Unmutated WT WT 
19361 Unmutated WT WT 
10872 Unmutated WT WT 
10650 Unmutated WT WT 
PMN059 Unmutated WT WT 
10320 Unmutated WT WT 
 
